Structure elucidation of 3-[1-(6-methoxy-2-naphtyl)ethyl]-6-(2,4-dichlorophenyl)-7 H -1,2,4-triazolo[3,4- b ]-1,3,4-thiadiazine, C 23 H 18 Cl 2 N 4 OS from synchrotron X-ray powder diffraction
Source abstract
Abstract
The 3-[1-(6-methoxy-2-naphtyl)ethyl]-6-(2,4-dichlorophenyl)-7 H -1,2,4-triazolo[3,4- b ]-1,3,4-thiadiazine, C 23 H 18 Cl 2 N 4 OS compound was synthesized, as a member of the family of novel potential anticancer agents. The structure of the title compound was characterized by IR, 1 H-NMR, mass spectroscopy, and elemental analysis, previously. In this study, the crystal structure of this compound has been determined from synchrotron X-ray powder diffraction data. The crystal structure was solved by simulated annealing and the final structure was achieved by Rietveld refinement method using soft restrains on all interatomic bond lengths and angles. This compound crystallizes in space group P 21, Z = 2, with the unit-cell parameters a = 15.55645(11) Å, b = 8.61693(6) Å, c = 8.56702(6) Å, β = 104.3270(4)°, and V = 1112.68(1) Å 3 . In the crystal structure, strong C−H⋯ π and weak intermolecular hydrogen-bonding interactions link the molecules into a three-dimensional network. The molecules are in a head-to-head arrangement in the unit cell.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Synthesis and Characterization of Heterocyclic Compounds · Synthesis and biological activity · Synthesis of Tetrazole Derivatives
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. 10.1016/j.ejmech.2006.12.00610.1016/j.ejmech.2006.12.006 ↗
2. 10.1107/S002188980604211710.1107/S0021889806042117 ↗
3. 10.1016/j.ejmech.2009.01.00310.1016/j.ejmech.2009.01.003 ↗
4. 10.1107/S002188986900664910.1107/S0021889869006649 ↗
5. 10.1154/1.176315210.1154/1.1763152 ↗
6. 10.1016/j.bmc.2016.01.01310.1016/j.bmc.2016.01.013 ↗
7. 10.1016/j.ejmech.2009.09.01010.1016/j.ejmech.2009.09.010 ↗
8. 10.1016/j.tips.2013.06.00510.1016/j.tips.2013.06.005 ↗
9. 10.1186/1758-2946-4-1710.1186/1758-2946-4-17 ↗
10. 10.1107/S160053681103645210.1107/S1600536811036452 ↗
11. 10.1107/S002188981202911110.1107/S0021889812029111 ↗
12. 10.1016/j.bmcl.2009.09.09610.1016/j.bmcl.2009.09.096 ↗
13. Coelho · 2009
14. Lauffer D. , Li P. and Mcginty K. (2010). Amino pyrazole triazole thiadiazole inhibitors of c-Met protein kinase, WO2010138665A1.
15. 10.1107/S002188989400421810.1107/S0021889894004218 ↗
16. 10.1016/j.ejmech.2014.03.04610.1016/j.ejmech.2014.03.046 ↗
17. 10.1016/S1470-2045(09)70035-X10.1016/S1470-2045(09)70035-X ↗
18. 10.1107/S002188980000642710.1107/S0021889800006427 ↗
19. 10.1107/S002188981002559810.1107/S0021889810025598 ↗
20. Role of COX-2 selective inhibitors for prevention and treatment of cancer
21. 10.1107/S002188980804272610.1107/S0021889808042726 ↗
22. 10.1007/s11224-010-9613-y10.1007/s11224-010-9613-y ↗
23. 10.1107/S002188988708709010.1107/S0021889887087090 ↗
24. 10.1107/S160053681201741210.1107/S1600536812017412 ↗
25. Lauffer D. , Aronov A. , Li P. , Deininger D. , Mcginty K. , Stamos D. , Come J. and Stewart M. (2007). Preparation of fused triazoles as inhibitors of c-Met tyrosine kinase, WO2007064797.
26. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
27. Zhang F. J. , Vojkovsky T. , Huang P. , Liang C. , Do S. H. , Koenig M. and Cui J. (2005). Triazolotriazine compounds and uses thereof, WO2005010005A1.
28. 10.1021/jm800043g10.1021/jm800043g ↗
29. 10.1016/j.ejmech.2009.06.02610.1016/j.ejmech.2009.06.026 ↗
30. 10.1107/S002188989100644110.1107/S0021889891006441 ↗
31. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy
32. 10.1107/S002188980600731X10.1107/S002188980600731X ↗
33. 10.1016/0921-4526(93)90108-I10.1016/0921-4526(93)90108-I ↗
34. 10.1107/S002188980202211210.1107/S0021889802022112 ↗
35. 10.1016/j.bmc.2014.08.02610.1016/j.bmc.2014.08.026 ↗
36. 10.1107/S010827011101806310.1107/S0108270111018063 ↗